After positive results in phase 3 trials, a GSK experimental therapy could be the first ultra-long-acting biologic approved for severe asthma.
The drug candidate, depemokimab, was measured in severe asthma patients with Type 2 inflammation characterized by blood eosinophil count, GSK said in a May 21 news release. Compared to a placebo, study participants who took depemokimab experienced fewer asthma attacks over 52 weeks.
The biologic is designed to be administered twice a year, and it's the first ultra-long-acting severe asthma treatment to be tested in a phase 3 trial, the release said. GSK said it plans to share more data at an upcoming conference and file for regulatory approval.